Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ilan Ganot received a new stock option grant. The Form 4 reports an award of 77,500 Director Stock Options, each exercisable for one share of common stock at an exercise price of $6.61 per share.

The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholders’ meeting after the grant. Any remaining unvested portion will also vest automatically upon specified change in control events. Following this award, Ganot directly holds options for 77,500 underlying shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ganot Ilan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Director stock options granted: 77,500 options Exercise price: $6.61 per share Underlying shares: 77,500 shares +2 more

5 metrics

Director stock options granted 77,500 options Grant to director Ilan Ganot on June 10, 2026

Exercise price $6.61 per share Strike price for Director Stock Option

Underlying shares 77,500 shares Common stock underlying the option grant

Expiration date June 10, 2036 Option expiration for director grant

Shares following transaction 77,500 options Total options held by Ganot after grant

Key Terms

Director Stock Option, grant/award acquisition, exercise price, change in control events, +1 more

5 terms

Director Stock Option financial

"The Form 4 reports an award of 77,500 Director Stock Options"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"each exercisable for one share of common stock at an exercise price of $6.61"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control events financial

"will vest automatically as to 100% of the unvested portion of such option upon specified change in control events"

vesting financial

"and vests in full on the earlier of the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ by Kimberly Cornwell as attorney-in-fact for Ilan Ganot	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Solid Biosciences (SLDB) director Ilan Ganot report on this Form 4?

Director Ilan Ganot reported receiving a stock option grant from Solid Biosciences. The award covers 77,500 Director Stock Options, each tied to one share of common stock, reflecting routine equity-based director compensation.

How many options did Ilan Ganot receive from Solid Biosciences (SLDB)?

Ilan Ganot received 77,500 Director Stock Options. Each option represents the right to buy one share of Solid Biosciences common stock, giving him derivative exposure to 77,500 underlying shares, subject to vesting conditions and the stated exercise price.

What is the exercise price of Ilan Ganot’s Solid Biosciences (SLDB) options?

The options have an exercise price of $6.61 per share. This means Ganot can buy Solid Biosciences common stock at $6.61 for each of the 77,500 underlying shares once the options vest and before they expire.

When do Ilan Ganot’s Solid Biosciences (SLDB) options vest?

The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual stockholders’ meeting, with any unvested portion also vesting upon specified change in control events.

When do the Solid Biosciences (SLDB) options granted to Ilan Ganot expire?

The granted Director Stock Options expire on June 10, 2036. Ganot must exercise the options, once vested, on or before that expiration date to purchase the underlying common shares at the fixed exercise price of $6.61.

How many Solid Biosciences (SLDB) options does Ilan Ganot hold after this transaction?

After this award, Ganot directly holds options covering 77,500 shares of Solid Biosciences common stock. The filing indicates this total as his holdings following the transaction reported in this Form 4.